Published in Blood on August 27, 2007
Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. Haematologica (2009) 1.43
Stochastic dynamics and the evolution of mutations in stem cells. BMC Biol (2011) 0.95
Aging stem cells, latexin, and longevity. Exp Cell Res (2008) 0.94
Dynamics of haemopoiesis across mammals. Proc Biol Sci (2008) 0.80
Evolutionary dynamics of chronic myeloid leukemia. Genes Cancer (2010) 0.80
The ecology of cancer from an evolutionary game theory perspective. Interface Focus (2014) 0.75
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Social diversity promotes the emergence of cooperation in public goods games. Nature (2008) 4.45
Cooperation prevails when individuals adjust their social ties. PLoS Comput Biol (2006) 3.91
Genetic progression and the waiting time to cancer. PLoS Comput Biol (2007) 3.57
Stochastic dynamics of invasion and fixation. Phys Rev E Stat Nonlin Soft Matter Phys (2006) 3.10
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc (2006) 2.88
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol (2009) 2.50
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood (2011) 2.45
Pairwise comparison and selection temperature in evolutionary game dynamics. J Theor Biol (2007) 2.41
Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood (2010) 2.40
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood (2009) 2.12
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol (2013) 2.01
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood (2012) 1.91
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol (2012) 1.87
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood (2009) 1.86
Risk of collective failure provides an escape from the tragedy of the commons. Proc Natl Acad Sci U S A (2011) 1.80
Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma (2010) 1.78
Stochastic dynamics of hematopoietic tumor stem cells. Cell Cycle (2007) 1.68
Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood (2005) 1.66
Breaking the symmetry between interaction and replacement in evolutionary dynamics on graphs. Phys Rev Lett (2007) 1.58
Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant (2009) 1.56
Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol (2005) 1.56
Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc (2011) 1.53
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant (2011) 1.51
Stochasticity and evolutionary stability. Phys Rev E Stat Nonlin Soft Matter Phys (2006) 1.48
Evolution of cooperation under N-person snowdrift games. J Theor Biol (2009) 1.47
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood (2011) 1.46
Cyclic neutropenia in mammals. Am J Hematol (2008) 1.43
Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. Haematologica (2009) 1.43
Evolutionary graph theory: breaking the symmetry between interaction and replacement. J Theor Biol (2007) 1.40
Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. Am J Hematol (2008) 1.39
Stochastic payoff evaluation increases the temperature of selection. J Theor Biol (2006) 1.38
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc (2010) 1.32
Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood (2012) 1.32
The role of diversity in the evolution of cooperation. J Theor Biol (2011) 1.27
Climate policies under wealth inequality. Proc Natl Acad Sci U S A (2014) 1.25
Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer (2011) 1.20
Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. Eur J Haematol (2008) 1.19
Modeling of cancer virotherapy with recombinant measles viruses. J Theor Biol (2008) 1.19
Compartmental architecture and dynamics of hematopoiesis. PLoS One (2007) 1.19
High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood (2011) 1.19
Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer. AJR Am J Roentgenol (2010) 1.14
Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene. AJR Am J Roentgenol (2009) 1.13
Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc (2008) 1.13
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol (2011) 1.11
Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders. Br J Haematol (2008) 1.09
Smoldering multiple myeloma requiring treatment: time for a new definition? Blood (2013) 1.09
Relationship between depth of response and outcome in multiple myeloma. J Clin Oncol (2007) 1.09
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood (2012) 1.08
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol (2010) 1.08
Schnitzler syndrome: an under-diagnosed clinical entity. Haematologica (2013) 1.07
Adaptive contact networks change effective disease infectiousness and dynamics. PLoS Comput Biol (2010) 1.06
Neutral evolution in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A (2008) 1.05
Allometric scaling of the active hematopoietic stem cell pool across mammals. PLoS One (2006) 1.05
From local to global dilemmas in social networks. PLoS One (2012) 1.02
Outcomes of patients with POEMS syndrome treated initially with radiation. Blood (2013) 1.02
Trends and outcomes of modern staging of solitary plasmacytoma of bone. Am J Hematol (2012) 1.01
Dynamics of N-person snowdrift games in structured populations. J Theor Biol (2012) 1.01
Dynamics of mutant cells in hierarchical organized tissues. PLoS Comput Biol (2011) 0.99
Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol (2013) 0.99
On the dynamics of neutral mutations in a mathematical model for a homogeneous stem cell population. J R Soc Interface (2012) 0.97
Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer (2012) 0.97
On the origin of multiple mutant clones in paroxysmal nocturnal hemoglobinuria. Stem Cells (2007) 0.96
Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant (2012) 0.95
Stochastic dynamics and the evolution of mutations in stem cells. BMC Biol (2011) 0.95
Co-evolution of pre-play signaling and cooperation. J Theor Biol (2011) 0.94
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. Br J Haematol (2011) 0.94
Multiple mutant clones in blood rarely coexist. Phys Rev E Stat Nonlin Soft Matter Phys (2008) 0.94
The emergence of tumor metastases. Cancer Biol Ther (2007) 0.93
Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. Am J Hematol (2009) 0.92
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood (2011) 0.90
Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia. Cancer (2005) 0.89
A deterministic model for the occurrence and dynamics of multiple mutations in hierarchically organized tissues. J R Soc Interface (2013) 0.87
Optimization of virotherapy for cancer. Bull Math Biol (2009) 0.87
Reward from punishment does not emerge at all costs. PLoS Comput Biol (2013) 0.87
Cancer biology: infectious tumour cells. Nature (2006) 0.87
Escaping the tragedy of the commons via directed investments. J Theor Biol (2011) 0.87
Ontogenic growth of the haemopoietic stem cell pool in humans. Proc Biol Sci (2007) 0.87
The evolution of prompt reaction to adverse ties. BMC Evol Biol (2008) 0.87
Evolution of collective action in adaptive social structures. Sci Rep (2013) 0.86
Intestinal lymphangiectasia with protein-losing enteropathy in Waldenstrom macroglobulinemia. Medicine (Baltimore) (2007) 0.86
Angiomatoid fibrous histiocytoma in a 25-year-old male. Rare Tumors (2010) 0.86
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood (2012) 0.86
A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision? Haematologica (2013) 0.85
Somatic mutations and the hierarchy of hematopoiesis. Bioessays (2010) 0.85
Reproductive fitness advantage of BCR-ABL expressing leukemia cells. Cancer Lett (2010) 0.85
Serum M-spike and transplant outcome in patients with multiple myeloma. Cancer Sci (2007) 0.84
Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol (2013) 0.83
Modeling the architecture and dynamics of hematopoiesis. Wiley Interdiscip Rev Syst Biol Med (2010) 0.83
Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma. Am J Hematol (2011) 0.83
Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. Am J Hematol (2014) 0.83